gentamicin 80 mg/2 ml soluţie injectabilă
dita estfarm srl - gentamicinum - soluţie injectabilă - 80 mg/2 ml
glucoză 400 mg/ml soluţie injectabilă
dita estfarm srl - glucoza - soluţie injectabilă - 400 mg/ml
glucoză 400 mg/ml soluţie injectabilă
dita estfarm srl - glucoza - soluţie injectabilă - 400 mg/ml
rituximab amring 100 mg 100 mg/10 ml concentrat pentru soluţie perfuzabilă
amring farma srl, românia - rituximabum - concentrat pentru soluţie perfuzabilă - 100 mg/10 ml
rituximab amring 500 mg 500 mg/50 ml concentrat pentru soluţie perfuzabilă
amring farma srl, românia - rituximabum - concentrat pentru soluţie perfuzabilă - 500 mg/50 ml
cefazolin 1 g pulbere pentru soluţie injectabilă/perfuzabilă
troge medical gmbh - cefazolinum - pulbere pentru soluţie injectabilă/perfuzabilă - 1 g
boostrix
glaxosmithkline biologicals sa - belgia - vaccin difteric,tetanic,pertussis - susp. inj. in seringa preumpluta - vaccinuri bacteriene vaccinuri pertussis
alyssum 7 mg/ml
sopharma ad - bulgaria - plante (extract de iedera) - sirop - 7mg/ml - expectorante excl. combinatii cu antitusive expectorante
clindamicina hameln 150 mg/ml
siegfried hameln gmbh - germania - clindamycinum - sol. inj./perf. - 150mg/ml - macrolide, lincosamide si streptogramine lincosamide
plerixafor accord
accord healthcare s.l.u. - plerixafor - multiple myeloma; hematopoietic stem cell transplantation - imunostimulante, - adult patientsplerixafor accord is indicated in combination with granulocyte-colony stimulating factor (g-csf) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma or multiple myeloma whose cells mobilise poorly (see section 4. paediatric patients (1 to less than 18 years)plerixafor accord is indicated in combination with g-csf to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children with lymphoma or solid malignant tumours, either:- pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilization with g-csf (with or without chemotherapy) is expected to be insufficient with regards to desired hematopoietic stem cells yield, or- who previously failed to collect sufficient haematopoietic stem cells (see section 4.